Jump to content

J. Keith Joung: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
mNo edit summary
Tags: Mobile edit Mobile web edit
 
(47 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{Short description|American pathologist and molecular biologist}}
{{BLP sources|date=November 2016}}
'''J. Keith Joung''' is an American pathologist and molecular biologist who is a Professor of Pathology at [[Harvard Medical School]] and the Desmond and Ann Heathwood Research Scholar at [[Massachusetts General Hospital]].<ref name="massgeneral">{{cite web|url=http://www.massgeneral.org/pathology/research/researchlab.aspx?id=1271|publisher=massgeneral.org|title=Joung Laboratory - Massachusetts General Hospital, Boston, MA|accessdate=2016-11-19}}</ref> He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.<ref>https://www.pnas.org/content/113/18/4884</ref>
'''J. Keith Joung''' is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology<ref>{{cite web |title=Keith Joung, MD, PhD, was recognized as the inaugural incumbent of the Robert B. Colvin Endowed Chair in Patholog |url=https://www.massgeneral.org/pathology/news/joung-jan-2020}}</ref> at [[Massachusetts General Hospital]] and is Professor of Pathology at [[Harvard Medical School]].<ref name="massgeneral">{{cite web|url=http://www.massgeneral.org/pathology/research/researchlab.aspx?id=1271|publisher=massgeneral.org|title=Joung Laboratory - Massachusetts General Hospital, Boston, MA|access-date=2016-11-19}}</ref> He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.<ref>{{cite journal |last1=Nair |first1=Prashant |title=QnAs with Jennifer Doudna |journal=Proceedings of the National Academy of Sciences |date=3 May 2016 |volume=113 |issue=18 |pages=4884–4886 |doi=10.1073/pnas.1605008113 |pmid=27092008 |pmc=4983843 |bibcode=2016PNAS..113.4884N |s2cid=8873309 |doi-access=free }}</ref>


==Education==
==Education==
In 1987, Joung graduated from [[Harvard University|Harvard College]] with a bachelor's degree in Biochemical Sciences.<ref>https://www.asgct.org/about/board-officers/j-keith-joung-md-phd</ref> He received an M.D. from Harvard Medical School and a Ph.D. in Genetics from Harvard University.<ref>https://ccib.mgh.harvard.edu/joung#research</ref>
In 1987, Joung graduated from [[Harvard University|Harvard College]] with a bachelor's degree in biochemical sciences.<ref>{{Cite web |url=https://www.asgct.org/about/board-officers/j-keith-joung-md-phd |title=J Keith Joung MD PhD &#124; Advisory Council &#124; ASGCT - American Society of Gene & Cell Therapy &#124; ASGCT - American Society of Gene & Cell Therapy |access-date=2019-03-05 |archive-date=2019-03-06 |archive-url=https://web.archive.org/web/20190306111742/https://www.asgct.org/about/board-officers/j-keith-joung-md-phd |url-status=dead }}</ref> He received an M.D. from [[Harvard Medical School]] and a Ph.D. in genetics from [[Harvard University]].<ref>{{Cite web|url=https://ccib.mgh.harvard.edu/joung#research|title = Center for Computational and Integrative Biology}}</ref>


==Career==
==Career==
Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.<ref>https://www.nytimes.com/2009/12/29/health/research/29zinc.html</ref><ref>https://www.sciencedaily.com/releases/2014/12/141216154729.htm</ref><ref>https://www.genomeweb.com/gene-silencinggene-editing/crispr-researchers-develop-highly-sensitive-method-identification-target#.XH8ifqeZNZ1</ref> In the mid-2000s, Joung's research was focused on creating zinc finger nuclease tools for biological research and gene therapy.<ref>https://www.massgeneral.org/about/pressrelease.aspx?id=1031</ref> He was the leader and founder of the [[Zinc finger|Zinc Finger]] Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.<ref name="zincfingers">{{cite web|url=http://www.zincfingers.org/consortium-members.htm|publisher=zincfingers.org|title=The Zinc Finger Consortium &#124; Consortium Members|accessdate=2016-11-19}}</ref><ref>{{Cite journal|last=Maeder|first=Morgan L.|last2=Thibodeau-Beganny|first2=Stacey|last3=Osiak|first3=Anna|last4=Wright|first4=David A.|last5=Anthony|first5=Reshma M.|last6=Eichtinger|first6=Magdalena|last7=Jiang|first7=Tao|last8=Foley|first8=Jonathan E.|last9=Winfrey|first9=Ronnie J.|date=2008-07-25|title=Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification|journal=Molecular Cell|volume=31|issue=2|pages=294–301|doi=10.1016/j.molcel.2008.06.016|issn=1097-2765|pmc=2535758|pmid=18657511}}</ref>
Joung is most well known for his work in [[genome editing]] and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.<ref name=Wade20091229>{{cite news |last1=Wade |first1=Nicholas |title=In New Way to Edit DNA, Hope for Treating Disease |url=https://www.nytimes.com/2009/12/29/health/research/29zinc.html |work=The New York Times |date=28 December 2009 }}</ref><ref name=pmid25513782>{{cite journal |last1=Tsai |first1=Shengdar Q. |last2=Zheng |first2=Zongli |last3=Nguyen |first3=Nhu T. |last4=Liebers |first4=Matthew |last5=Topkar |first5=Ved V. |last6=Thapar |first6=Vishal |last7=Wyvekens |first7=Nicolas |last8=Khayter |first8=Cyd |last9=Iafrate |first9=A. John |last10=Le |first10=Long P. |last11=Aryee |first11=Martin J. |last12=Joung |first12=J. Keith |title=GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases |journal=Nature Biotechnology |date=February 2015 |volume=33 |issue=2 |pages=187–197 |doi=10.1038/nbt.3117 |pmid=25513782 |pmc=4320685}}
*{{cite press release |date=December 16, 2014 |title=New method identifies genome-wide off-target cleavage sites of CRISPR-Cas nucleases |website=ScienceDaily |url=https://www.sciencedaily.com/releases/2014/12/141216154729.htm}}</ref><ref>{{Cite web|url=https://www.genomeweb.com/gene-silencinggene-editing/crispr-researchers-develop-highly-sensitive-method-identification-target#.XH8ifqeZNZ1|title=CRISPR Researchers Develop Highly Sensitive Method for Identification of Off-Target Effects in Vivo|date=12 September 2018}}</ref> In the mid-2000s, his research was focused on creating [[zinc finger nuclease]] tools for biological research and gene therapy.<ref name=Wade20091229/> He was the leader and founder of the [[Zinc finger|Zinc Finger]] Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.<ref name="zincfingers">{{cite web|url=http://www.zincfingers.org/consortium-members.htm|publisher=zincfingers.org|title=The Zinc Finger Consortium &#124; Consortium Members|access-date=2016-11-19}}</ref><ref>{{cite journal |last1=Maeder |first1=Morgan L. |last2=Thibodeau-Beganny |first2=Stacey |last3=Osiak |first3=Anna |last4=Wright |first4=David A. |last5=Anthony |first5=Reshma M. |last6=Eichtinger |first6=Magdalena |last7=Jiang |first7=Tao |last8=Foley |first8=Jonathan E. |last9=Winfrey |first9=Ronnie J. |last10=Townsend |first10=Jeffrey A. |last11=Unger-Wallace |first11=Erica |last12=Sander |first12=Jeffry D. |last13=Müller-Lerch |first13=Felix |last14=Fu |first14=Fengli |last15=Pearlberg |first15=Joseph |last16=Göbel |first16=Carl |last17=Dassie |first17=Justin P. |last18=Pruett-Miller |first18=Shondra M. |last19=Porteus |first19=Matthew H. |last20=Sgroi |first20=Dennis C. |last21=Iafrate |first21=A. John |last22=Dobbs |first22=Drena |last23=McCray |first23=Paul B. |last24=Cathomen |first24=Toni |last25=Voytas |first25=Daniel F. |last26=Joung |first26=J. Keith |author-link19=Matthew Porteus |title=Rapid 'Open-Source' Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification |journal=Molecular Cell |date=July 2008 |volume=31 |issue=2 |pages=294–301 |doi=10.1016/j.molcel.2008.06.016 |pmid=18657511 |pmc=2535758 }}</ref>


More recently, Joung has contributed to the development of TAL effector, TALENs, and the RNA-guided CRISPR/Cas9 system. In addition to demonstrating the use of the CRISPR/Cas9 system ''in vivo'' through the zebrafish model,<ref>Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR*, Joung JK*. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013 Mar;31(3):227-9.</ref> Joung has pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.<ref>Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2015)</ref><ref>{{Cite journal|last=Tsai|first=Shengdar Q.|last2=Nguyen|first2=Nhu T.|last3=Malagon-Lopez|first3=Jose|last4=Topkar|first4=Ved V.|last5=Aryee|first5=Martin J.|last6=Joung|first6=J. Keith|date=June 2017|title=CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets|url=https://www.nature.com/nmeth/journal/v14/n6/full/nmeth.4278.html|journal=Nature Methods|language=en|volume=14|issue=6|pages=607–614|doi=10.1038/nmeth.4278|issn=1548-7091}}</ref> In 2016, his group became one of the first to report engineered high-fidelity CRISPR-Cas9 nucleases (HF1) with no detectable off-target effects.<ref>{{Cite journal|last=Kleinstiver|first=Benjamin P.|last2=Pattanayak|first2=Vikram|last3=Prew|first3=Michelle S.|last4=Tsai|first4=Shengdar Q.|last5=Nguyen|first5=Nhu T.|last6=Zheng|first6=Zongli|last7=Joung|first7=J. Keith|date=2016-01-28|title=High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects|journal=Nature|volume=529|issue=7587|pages=490–495|doi=10.1038/nature16526|issn=1476-4687|pmc=4851738|pmid=26735016}}</ref>
More recently, he contributed to the development of TAL effector, [[TALENs]], and the RNA-guided [[CRISPR/Cas9]] system. In addition to demonstrating the use of the CRISPR/Cas9 system [[in vivo]] through the zebrafish model,<ref>{{cite journal |last1=Hwang |first1=Woong Y. |last2=Fu |first2=Yanfang |last3=Reyon |first3=Deepak |last4=Maeder |first4=Morgan L. |last5=Tsai |first5=Shengdar Q. |last6=Sander |first6=Jeffry D. |last7=Peterson |first7=Randall T. |last8=Yeh |first8=J.-R. Joanna |last9=Joung |first9=J. Keith |title=Efficient genome editing in zebrafish using a CRISPR-Cas system |journal=Nature Biotechnology |date=March 2013 |volume=31 |issue=3 |pages=227–229 |doi=10.1038/nbt.2501 |pmid=23360964 |pmc=3686313 }}</ref> he pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.<ref name=pmid25513782/><ref>{{cite journal |last1=Tsai |first1=Shengdar Q. |last2=Nguyen |first2=Nhu T. |last3=Malagon-Lopez |first3=Jose |last4=Topkar |first4=Ved V. |last5=Aryee |first5=Martin J. |last6=Joung |first6=J. Keith |title=CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets |journal=Nature Methods |date=June 2017 |volume=14 |issue=6 |pages=607–614 |doi=10.1038/nmeth.4278 |pmid=28459458 |pmc=5924695 }}</ref> In 2016, his group became one of the first to report engineered high-fidelity CRISPR/Cas9 nucleases (HF1) with no detectable off-target effects.<ref>{{cite journal |last1=Kleinstiver |first1=Benjamin P. |last2=Pattanayak |first2=Vikram |last3=Prew |first3=Michelle S. |last4=Tsai |first4=Shengdar Q. |last5=Nguyen |first5=Nhu T. |last6=Zheng |first6=Zongli |last7=Joung |first7=J. Keith |title=High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects |journal=Nature |date=January 2016 |volume=529 |issue=7587 |pages=490–495 |doi=10.1038/nature16526 |pmid=26735016 |pmc=4851738 |bibcode=2016Natur.529..490K }}</ref>


Joung is also one of the scientific co-founders of [[Editas Medicine]], along with [[Jennifer Doudna]], [[Feng Zhang]], [[George M. Church|George Church]], and [[David R. Liu|David Liu]].<ref>https://mcgovern.mit.edu/2013/11/25/editas-medicine-to-develop-new-class-of-genome-editing-therapeutics/</ref/
He is one of the scientific co-founders of [[Editas Medicine]], along with [[Jennifer Doudna]], [[Feng Zhang]], [[George M. Church|George Church]], and [[David R. Liu|David Liu]].<ref>{{Cite web|url=https://mcgovern.mit.edu/2013/11/25/editas-medicine-to-develop-new-class-of-genome-editing-therapeutics/|title = Editas Medicine to develop new class of genome editing therapeutics|date = 25 November 2013}}</ref> He is also a co-founder of [[Beam Therapeutics]] and Verve Therapeutics.<ref>{{cite web |title=FOUNDERS AND INVENTORS |url=https://beamtx.com/about-us/ |website=Beam Therapeutics |access-date=14 December 2022}}</ref><ref>{{cite web |title=About Us |url=https://www.vervetx.com/about-us/ |website=Verve Therapeutics |access-date=5 July 2021}}</ref> He received the [[Ho-Am Prize in Medicine]] in 2022 <ref>{{cite web |url= https://newsis.com/view/?id=NISX20220531_0001892407 |title= 32회 삼성호암상…오용근 포스텍 교수 등 6인 수상 |author=이인준 |date= 31 May 2022 |website= Newsis |publisher= |access-date= 3 June 2022 |quote= |language= Korean}}</ref> and the American Society of Gene and Cell Therapy Outstanding Achievement Award in 2023, the society's highest honor.<ref>{{cite web |url= https://asgct.org/publications/news/april-2023/am23-awards-announcement}}</ref>

He has an [[h-index]] of 85 according to [[Semantic Scholar]].<ref>{{cite web |title=J. Joung |url=https://www.semanticscholar.org/author/J.-Joung/144322129?sort=pub-date |website=[[Semantic Scholar]] |access-date=14 December 2022}}</ref>


==References==
==References==
Line 20: Line 23:
[[Category:Year of birth missing (living people)]]
[[Category:Year of birth missing (living people)]]
[[Category:Living people]]
[[Category:Living people]]
⚫
[[Category:Harvard Medical School faculty]]
⚫
[[Category:Harvard Medical School alumni]]
[[Category:American pathologists]]
[[Category:American pathologists]]
[[Category:Genome editing]]
[[Category:Harvard College alumni]]
⚫
[[Category:Harvard Medical School alumni]]
⚫
[[Category:Harvard Medical School faculty]]
[[Category:Physicians of Massachusetts General Hospital]]
[[Category:Physicians of Massachusetts General Hospital]]
[[Category:Recipients of the Ho-Am Prize in Medicine]]

Latest revision as of 17:03, 29 May 2023

J. Keith Joung is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology[1] at Massachusetts General Hospital and is Professor of Pathology at Harvard Medical School.[2] He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.[3]

Education

[edit]

In 1987, Joung graduated from Harvard College with a bachelor's degree in biochemical sciences.[4] He received an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University.[5]

Career

[edit]

Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.[6][7][8] In the mid-2000s, his research was focused on creating zinc finger nuclease tools for biological research and gene therapy.[6] He was the leader and founder of the Zinc Finger Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.[9][10]

More recently, he contributed to the development of TAL effector, TALENs, and the RNA-guided CRISPR/Cas9 system. In addition to demonstrating the use of the CRISPR/Cas9 system in vivo through the zebrafish model,[11] he pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.[7][12] In 2016, his group became one of the first to report engineered high-fidelity CRISPR/Cas9 nucleases (HF1) with no detectable off-target effects.[13]

He is one of the scientific co-founders of Editas Medicine, along with Jennifer Doudna, Feng Zhang, George Church, and David Liu.[14] He is also a co-founder of Beam Therapeutics and Verve Therapeutics.[15][16] He received the Ho-Am Prize in Medicine in 2022 [17] and the American Society of Gene and Cell Therapy Outstanding Achievement Award in 2023, the society's highest honor.[18]

He has an h-index of 85 according to Semantic Scholar.[19]

References

[edit]
  1. ^ "Keith Joung, MD, PhD, was recognized as the inaugural incumbent of the Robert B. Colvin Endowed Chair in Patholog".
  2. ^ "Joung Laboratory - Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 2016-11-19.
  3. ^ Nair, Prashant (3 May 2016). "QnAs with Jennifer Doudna". Proceedings of the National Academy of Sciences. 113 (18): 4884–4886. Bibcode:2016PNAS..113.4884N. doi:10.1073/pnas.1605008113. PMC 4983843. PMID 27092008. S2CID 8873309.
  4. ^ "J Keith Joung MD PhD | Advisory Council | ASGCT - American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy". Archived from the original on 2019-03-06. Retrieved 2019-03-05.
  5. ^ "Center for Computational and Integrative Biology".
  6. ^ a b Wade, Nicholas (28 December 2009). "In New Way to Edit DNA, Hope for Treating Disease". The New York Times.
  7. ^ a b Tsai, Shengdar Q.; Zheng, Zongli; Nguyen, Nhu T.; Liebers, Matthew; Topkar, Ved V.; Thapar, Vishal; Wyvekens, Nicolas; Khayter, Cyd; Iafrate, A. John; Le, Long P.; Aryee, Martin J.; Joung, J. Keith (February 2015). "GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases". Nature Biotechnology. 33 (2): 187–197. doi:10.1038/nbt.3117. PMC 4320685. PMID 25513782.
  8. ^ "CRISPR Researchers Develop Highly Sensitive Method for Identification of Off-Target Effects in Vivo". 12 September 2018.
  9. ^ "The Zinc Finger Consortium | Consortium Members". zincfingers.org. Retrieved 2016-11-19.
  10. ^ Maeder, Morgan L.; Thibodeau-Beganny, Stacey; Osiak, Anna; Wright, David A.; Anthony, Reshma M.; Eichtinger, Magdalena; Jiang, Tao; Foley, Jonathan E.; Winfrey, Ronnie J.; Townsend, Jeffrey A.; Unger-Wallace, Erica; Sander, Jeffry D.; Müller-Lerch, Felix; Fu, Fengli; Pearlberg, Joseph; Göbel, Carl; Dassie, Justin P.; Pruett-Miller, Shondra M.; Porteus, Matthew H.; Sgroi, Dennis C.; Iafrate, A. John; Dobbs, Drena; McCray, Paul B.; Cathomen, Toni; Voytas, Daniel F.; Joung, J. Keith (July 2008). "Rapid 'Open-Source' Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification". Molecular Cell. 31 (2): 294–301. doi:10.1016/j.molcel.2008.06.016. PMC 2535758. PMID 18657511.
  11. ^ Hwang, Woong Y.; Fu, Yanfang; Reyon, Deepak; Maeder, Morgan L.; Tsai, Shengdar Q.; Sander, Jeffry D.; Peterson, Randall T.; Yeh, J.-R. Joanna; Joung, J. Keith (March 2013). "Efficient genome editing in zebrafish using a CRISPR-Cas system". Nature Biotechnology. 31 (3): 227–229. doi:10.1038/nbt.2501. PMC 3686313. PMID 23360964.
  12. ^ Tsai, Shengdar Q.; Nguyen, Nhu T.; Malagon-Lopez, Jose; Topkar, Ved V.; Aryee, Martin J.; Joung, J. Keith (June 2017). "CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets". Nature Methods. 14 (6): 607–614. doi:10.1038/nmeth.4278. PMC 5924695. PMID 28459458.
  13. ^ Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Zheng, Zongli; Joung, J. Keith (January 2016). "High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects". Nature. 529 (7587): 490–495. Bibcode:2016Natur.529..490K. doi:10.1038/nature16526. PMC 4851738. PMID 26735016.
  14. ^ "Editas Medicine to develop new class of genome editing therapeutics". 25 November 2013.
  15. ^ "FOUNDERS AND INVENTORS". Beam Therapeutics. Retrieved 14 December 2022.
  16. ^ "About Us". Verve Therapeutics. Retrieved 5 July 2021.
  17. ^ 이인준 (31 May 2022). "32회 삼성호암상…오용근 포스텍 교수 등 6인 수상". Newsis (in Korean). Retrieved 3 June 2022.
  18. ^ https://asgct.org/publications/news/april-2023/am23-awards-announcement. {{cite web}}: Missing or empty |title= (help)
  19. ^ "J. Joung". Semantic Scholar. Retrieved 14 December 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=J._Keith_Joung&oldid=1157591996"